The anterior cruciate ligament (ACL) is a commonly injured intra-articular ligament of the knee. Approximately 200,000 (ACL) injuries are reported annually in the United States. Over 75% of patients experiencing ACL injury opt for orthopedic reconstructive surgery 1,2,3,4. Surgical intervention is often indicated due to an inherently poor healing potential3. ACL reconstruction is typically accomplished by means of an autograft or allograft tendon. Autograft and allograft represent the gold standard for reconstruction as they boast high success rates, and primary suture repair, the other treatment option, has shown failure rates of up to 94% 5,6,7.
Partial tears of the ACL represent 10% to 28% of all ACL tears8. In a prospective study, Noyes et al. estimated that 50% of patients with partial tears affecting more than half of the ACL progressed to complete ACL insufficiency after non-operative treatment9. Other studies report persistent instability and decreased function with fewer than 30% of patients able to return to their pre-injury activity level 9,10,11,12,13. Treatment options are limited and include conservative modalities, thermal shrinkage of remaining ACL, or ACL reconstruction. Recently, there has been increased interest in augmented primary repair. These techniques use biologics to enhance primary suture repairs14. Recent research has attempted to harvest mesenchymal-like hACL derived stem cells to circumvent graft limitations,31,32 but the validity and efficacy of these cells is still unknown. The ideal cell source for tissue engineering applications seems to be non-mesechymal hACL derived fibroblast cells.
Current research is focused on identifying a suitable matrix material and cell source for the engineered scaffold. It is standard procedure for a torn ACL to be discarded as surgical waste during reconstruction surgery, however, this damaged ligament may be a quality source for the acquisition of cells needed to develop and enhance an ideal tissue engineered ACL replacement. Our lab has developed a protocol for the in vitro expansion of these harvested hACL derived cells. Using an engineered 2D matrix infused with hACL derived cells, we have designed a patch that could potentially augment partial ACL repair and strengthen torn ligaments.